Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Enjoy your FREE PREVIEW which shows only 2022 data and 25 documents. Contact Patent Forecast for full access.        


Read More News and Insights

GW Pharmaceutical creating CBDV medications for treating Autism, Schizophrenia

Z-ARCHIVE-Cannabis Patent Forecast®

June 20, 2019

A GW Pharmaceuticals cannabis patent application (2019/0160023) for the use of the cannabinoid cannabidivarin (CBDV) in the treatment of Autism, Schizophrenia, and related psychological disorders was published this month. Under GW Pharma’s Pharmaceutical Pipeline development, CBDV has entered into phase 2 of clinical trials. Once through phase 3, GW Pharma can submit an application to the FDA presenting their evidence to seek FDA approval of the purified CBDV drug, just as was done for their purified CBD drug Epidiolex.

Relevant Patent Documents

Application US20190160023  

Article Source Link

GW Pharmaceuticals

Read more like this in News This Week!   or   Share this link with your connections!